The  ||| S:0 E:4 ||| DT
usefulness  ||| S:4 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
platelet  ||| S:18 E:27 ||| JJ
function  ||| S:27 E:36 ||| NN
evaluation  ||| S:36 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
clinical  ||| S:50 E:59 ||| JJ
practice  ||| S:59 E:68 ||| NN
Platelets  ||| S:68 E:78 ||| RB
play  ||| S:78 E:83 ||| VB
a  ||| S:83 E:85 ||| DT
pivotal  ||| S:85 E:93 ||| JJ
role  ||| S:93 E:98 ||| NN
in  ||| S:98 E:101 ||| IN
the  ||| S:101 E:105 ||| DT
regulation  ||| S:105 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
both  ||| S:119 E:124 ||| DT
thrombosis  ||| S:124 E:135 ||| NN
and  ||| S:135 E:139 ||| CC
haemostasis ||| S:139 E:150 ||| NN
.  ||| S:150 E:152 ||| .
Functional  ||| S:152 E:163 ||| JJ
testing  ||| S:163 E:171 ||| NN
of  ||| S:171 E:174 ||| IN
platelet  ||| S:174 E:183 ||| JJ
response  ||| S:183 E:192 ||| NN
has  ||| S:192 E:196 ||| VBZ
been  ||| S:196 E:201 ||| VBN
exclusively  ||| S:201 E:213 ||| RB
used  ||| S:213 E:218 ||| VBN
in  ||| S:218 E:221 ||| IN
the  ||| S:221 E:225 ||| DT
diagnosis  ||| S:225 E:235 ||| NN
and  ||| S:235 E:239 ||| CC
management  ||| S:239 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
bleeding  ||| S:253 E:262 ||| VBG
disorders ||| S:262 E:271 ||| NNS
.  ||| S:271 E:273 ||| .
Recent  ||| S:273 E:280 ||| JJ
advances  ||| S:280 E:289 ||| NNS
of  ||| S:289 E:292 ||| IN
light  ||| S:292 E:298 ||| JJ
transmission  ||| S:298 E:311 ||| NN
aggregometry  ||| S:311 E:324 ||| NNS
and  ||| S:324 E:328 ||| CC
development  ||| S:328 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
more  ||| S:343 E:348 ||| RBR
useful  ||| S:348 E:355 ||| JJ
devices  ||| S:355 E:363 ||| NNS
have  ||| S:363 E:368 ||| VBP
demonstrated  ||| S:368 E:381 ||| VBN
the  ||| S:381 E:385 ||| DT
clinical  ||| S:385 E:394 ||| JJ
utility  ||| S:394 E:402 ||| NN
to  ||| S:402 E:405 ||| TO
enlarge  ||| S:405 E:413 ||| VB
platelet  ||| S:413 E:422 ||| JJ
function  ||| S:422 E:431 ||| NN
testing  ||| S:431 E:439 ||| NN
in  ||| S:439 E:442 ||| IN
patients  ||| S:442 E:451 ||| NNS
with  ||| S:451 E:456 ||| IN
cardiovascular  ||| S:456 E:471 ||| JJ
disease ||| S:471 E:478 ||| NN
.  ||| S:478 E:480 ||| .
The  ||| S:480 E:484 ||| DT
ex  ||| S:484 E:487 ||| JJ
vivo  ||| S:487 E:492 ||| JJ
measurement  ||| S:492 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
residual  ||| S:507 E:516 ||| JJ
platelet  ||| S:516 E:525 ||| JJ
response  ||| S:525 E:534 ||| NN
seems ||| S:534 E:539 ||| VBZ
,  ||| S:539 E:541 ||| ,
with  ||| S:541 E:546 ||| IN
some  ||| S:546 E:551 ||| DT
assays ||| S:551 E:557 ||| NN
,  ||| S:557 E:559 ||| ,
predictive  ||| S:559 E:570 ||| JJ
of  ||| S:570 E:573 ||| IN
adverse  ||| S:573 E:581 ||| JJ
clinical  ||| S:581 E:590 ||| JJ
events ||| S:590 E:596 ||| NNS
.  ||| S:596 E:598 ||| .
Still  ||| S:598 E:604 ||| RB
a  ||| S:604 E:606 ||| DT
debate ||| S:606 E:612 ||| NN
,  ||| S:612 E:614 ||| ,
it  ||| S:614 E:617 ||| PRP
represents  ||| S:617 E:628 ||| VBZ
an  ||| S:628 E:631 ||| DT
emerging  ||| S:631 E:640 ||| VBG
area  ||| S:640 E:645 ||| NN
of  ||| S:645 E:648 ||| IN
interest  ||| S:648 E:657 ||| NN
for  ||| S:657 E:661 ||| IN
both  ||| S:661 E:666 ||| PDT
the  ||| S:666 E:670 ||| DT
clinician  ||| S:670 E:680 ||| NN
and  ||| S:680 E:684 ||| CC
the  ||| S:684 E:688 ||| DT
basic  ||| S:688 E:694 ||| JJ
scientist ||| S:694 E:703 ||| NN
.  ||| S:703 E:705 ||| .
Heparin-induced  ||| S:705 E:721 ||| JJ
thrombocytopenia  ||| S:721 E:738 ||| JJ
diagnosis  ||| S:738 E:748 ||| NN
is  ||| S:748 E:751 ||| VBZ
also  ||| S:751 E:756 ||| RB
difficult  ||| S:756 E:766 ||| JJ
and  ||| S:766 E:770 ||| CC
a  ||| S:770 E:772 ||| DT
functional  ||| S:772 E:783 ||| JJ
assay  ||| S:783 E:789 ||| NN
is  ||| S:789 E:792 ||| VBZ
now  ||| S:792 E:796 ||| RB
available  ||| S:796 E:806 ||| JJ
for  ||| S:806 E:810 ||| IN
an  ||| S:810 E:813 ||| DT
easier  ||| S:813 E:820 ||| JJR
and  ||| S:820 E:824 ||| CC
rapid  ||| S:824 E:830 ||| JJ
method  ||| S:830 E:837 ||| NN
to  ||| S:837 E:840 ||| TO
rule  ||| S:840 E:845 ||| VB
out  ||| S:845 E:849 ||| RP
such  ||| S:849 E:854 ||| PDT
a  ||| S:854 E:856 ||| DT
life-threatening  ||| S:856 E:873 ||| JJ
situation ||| S:873 E:882 ||| NN
.  ||| S:882 E:884 ||| .
This  ||| S:884 E:889 ||| DT
review  ||| S:889 E:896 ||| NN
article  ||| S:896 E:904 ||| NN
will  ||| S:904 E:909 ||| MD
describe  ||| S:909 E:918 ||| VB
the  ||| S:918 E:922 ||| DT
available  ||| S:922 E:932 ||| JJ
methods  ||| S:932 E:940 ||| NNS
of  ||| S:940 E:943 ||| IN
measuring  ||| S:943 E:953 ||| VBG
platelet  ||| S:953 E:962 ||| JJ
response  ||| S:962 E:971 ||| NN
and  ||| S:971 E:975 ||| CC
will  ||| S:975 E:980 ||| MD
discuss  ||| S:980 E:988 ||| VB
both  ||| S:988 E:993 ||| PDT
the  ||| S:993 E:997 ||| DT
limitations  ||| S:997 E:1009 ||| NNS
and  ||| S:1009 E:1013 ||| CC
emerging  ||| S:1013 E:1022 ||| VBG
data  ||| S:1022 E:1027 ||| NNS
supporting  ||| S:1027 E:1038 ||| VBG
the  ||| S:1038 E:1042 ||| DT
role  ||| S:1042 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
platelet  ||| S:1050 E:1059 ||| JJ
function  ||| S:1059 E:1068 ||| NN
studies  ||| S:1068 E:1076 ||| NNS
in  ||| S:1076 E:1079 ||| IN
clinical  ||| S:1079 E:1088 ||| JJ
practice ||| S:1088 E:1096 ||| NN
.  ||| S:1096 E:1098 ||| .
